Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.
Linezoild is a monoamine oxidase
inhibitor (MAOI). This means that linezolid blocks the breakdown of compounds
that are normally broken down my monoamine oxidase enzymes. This increases the
levels of these compounds in the body and can increase the risk of side effects.
Linezolid should not be used by patients taking monoamine oxidase inhibitors
(MAOI) or within two weeks of taking an MAOI.
Linezolid should not be combined with pseudoephedrine, phenylephrine,
ephedrine, and phenylpropanolamine. The combination of linezolid and these drugs
can cause an acute hypertensive episode.
Monoamine oxidase also breaks down tyramine, a chemical present in aged
cheese, wines, and other aged foods. Since linezolid inhibits monoamine oxidase,
it decreases the breakdown of tyramine from ingested food, thus increasing the
level of tyramine in the body. Excessive tyramine can elevate blood pressure and
cause a hypertensive crisis. Patients treated with MAOIs and lInezolid should
adhere to recommended dietary modifications that reduce the intake of tyramine.
PREGNANCY AND BREASTFEEDING SAFETY: Linezolid has not been
adequately studied in pregnant women. It should be used during pregnancy only if
the potential benefit justifies the potential risk to the fetus. It is not known
whether linezolid is excreted in human milk.
STORAGE: Linezolid should be stored at room temperature 25 C
(77 F). Infusion bags should be kept in its overwrap and prevented from
The recommended adult dose for treating pneumonia or
complicated skin and skin structure infections is 600 mg orally or by
intravenous infusion every 12 hours for 10 to 14 days.
Uncomplicated skin and
skin structure infections are treated with 400 to 600 mg orally every 12 hours
for 10 to 14 days.
The dose for vancomycin-resistant Enterococcus faecium
infections is 600 mg orally or by intravenous infusion every 12 hours for 14 to
DRUG CLASS AND MECHANISM:
Linezolid (Zyvox) is a synthetic
antibiotic that is effective against bacteria such as Enterococcus faecium,
Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pneumoniae,
Streptococcus pyogenes, and others.
It is effective against Staphylococcus
aureus isolates that are resistant to other antibiotics.
bacteria from growing by interfering with their ability to make proteins.
Because proteins are made differently in people and bacteria, linezolid does not
interfere with production of proteins in humans.